146 related articles for article (PubMed ID: 21130662)
1. Functional in vivo imaging of cysteine cathepsin activity in murine model of inflammation.
Caglič D; Globisch A; Kindermann M; Lim NH; Jeske V; Juretschke HP; Bartnik E; Weithmann KU; Nagase H; Turk B; Wendt KU
Bioorg Med Chem; 2011 Feb; 19(3):1055-61. PubMed ID: 21130662
[TBL] [Abstract][Full Text] [Related]
2. Design, characterization and cellular uptake studies of fluorescence-labeled prototypic cathepsin inhibitors.
Kohl F; Schmitz J; Furtmann N; Schulz-Fincke AC; Mertens MD; Küppers J; Benkhoff M; Tobiasch E; Bartz U; Bajorath J; Stirnberg M; Gütschow M
Org Biomol Chem; 2015 Nov; 13(41):10310-23. PubMed ID: 26307943
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive quantitative tomography of the therapeutic response to dexamethasone in ovalbumin-induced murine asthma.
Korideck H; Peterson JD
J Pharmacol Exp Ther; 2009 Jun; 329(3):882-9. PubMed ID: 19293392
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive optical imaging of cysteine protease activity using fluorescently quenched activity-based probes.
Blum G; von Degenfeld G; Merchant MJ; Blau HM; Bogyo M
Nat Chem Biol; 2007 Oct; 3(10):668-77. PubMed ID: 17828252
[TBL] [Abstract][Full Text] [Related]
5. Revealing the inhibitory potential of Yersinia enterocolitica on cysteine proteases of the papain family.
Kędzior M; Pawlak A; Seredyński R; Bania J; Platt-Samoraj A; Czemplik M; Klausa E; Bugla-Płoskońska G; Gutowicz J
Microbiol Res; 2018 Mar; 207():211-225. PubMed ID: 29458857
[TBL] [Abstract][Full Text] [Related]
6. Cathepsins X and B display distinct activity profiles that can be exploited for inhibitor design.
Ménard R; Therrien C; Lachance P; Sulea T; Qo H; Alvarez-Hernandez AD; Roush WR
Biol Chem; 2001 May; 382(5):839-45. PubMed ID: 11517939
[TBL] [Abstract][Full Text] [Related]
7. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors.
Black WC; Percival MD
Chembiochem; 2006 Oct; 7(10):1525-35. PubMed ID: 16921579
[TBL] [Abstract][Full Text] [Related]
8. Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials.
Liu CL; Guo J; Zhang X; Sukhova GK; Libby P; Shi GP
Nat Rev Cardiol; 2018 Jun; 15(6):351-370. PubMed ID: 29679024
[TBL] [Abstract][Full Text] [Related]
9. Cysteine cathepsin proteases as pharmacological targets in cancer.
Palermo C; Joyce JA
Trends Pharmacol Sci; 2008 Jan; 29(1):22-8. PubMed ID: 18037508
[TBL] [Abstract][Full Text] [Related]
10. In vivo imaging of intraperitoneally disseminated tumors in model mice by using activatable fluorescent small-molecular probes for activity of cathepsins.
Fujii T; Kamiya M; Urano Y
Bioconjug Chem; 2014 Oct; 25(10):1838-46. PubMed ID: 25196809
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the cathepsin cysteine proteases B and K by square-planar cycloaurated gold(III) compounds and investigation of their anti-cancer activity.
Zhu Y; Cameron BR; Mosi R; Anastassov V; Cox J; Qin L; Santucci Z; Metz M; Skerlj RT; Fricker SP
J Inorg Biochem; 2011 May; 105(5):754-62. PubMed ID: 21481817
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design of cathepsin K inhibitors containing a benzyloxy-substituted benzoyl peptidomimetic.
Thompson SK; Smith WW; Zhao B; Halbert SM; Tomaszek TA; Tew DG; Levy MA; Janson CA; DAlessio KJ; McQueney MS; Kurdyla J; Jones CS; DesJarlais RL; Abdel-Meguid SS; Veber DF
J Med Chem; 1998 Oct; 41(21):3923-7. PubMed ID: 9767629
[TBL] [Abstract][Full Text] [Related]
13. Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins.
Chowdhury MA; Moya IA; Bhilocha S; McMillan CC; Vigliarolo BG; Zehbe I; Phenix CP
J Med Chem; 2014 Jul; 57(14):6092-104. PubMed ID: 24940640
[TBL] [Abstract][Full Text] [Related]
14. Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.
Tavares FX; Boncek V; Deaton DN; Hassell AM; Long ST; Miller AB; Payne AA; Miller LR; Shewchuk LM; Wells-Knecht K; Willard DH; Wright LL; Zhou HQ
J Med Chem; 2004 Jan; 47(3):588-99. PubMed ID: 14736240
[TBL] [Abstract][Full Text] [Related]
15. Fluorescent nitrile-based inhibitors of cysteine cathepsins.
Frizler M; Mertens MD; Gütschow M
Bioorg Med Chem Lett; 2012 Dec; 22(24):7715-8. PubMed ID: 23122525
[TBL] [Abstract][Full Text] [Related]
16. Cysteine Protease Zymography: Brief Review.
Wilkesman J
Methods Mol Biol; 2017; 1626():25-31. PubMed ID: 28608197
[TBL] [Abstract][Full Text] [Related]
17. Conformationally constrained 1,3-diamino ketones: a series of potent inhibitors of the cysteine protease cathepsin K.
Marquis RW; Yamashita DS; Ru Y; LoCastro SM; Oh HJ; Erhard KF; DesJarlais RL; Head MS; Smith WW; Zhao B; Janson CA; Abdel-Meguid SS; Tomaszek TA; Levy MA; Veber DF
J Med Chem; 1998 Sep; 41(19):3563-7. PubMed ID: 9733481
[No Abstract] [Full Text] [Related]
18. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics.
Yasuda Y; Kaleta J; Brömme D
Adv Drug Deliv Rev; 2005 May; 57(7):973-93. PubMed ID: 15876399
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
